Efficacy of Gemcitabine-based chemotherapy in clear cell sarcoma of soft tissue.
Cojocaru, Elena Thway, Khin Fisher, Cyril Messiou, Christina Zaidi, Shane Miah, Aisha B Benson, Charlotte Gennatas, Spyridon Huang, Paul Jones, Robin L
Cojocaru, Elena
Thway, Khin
Fisher, Cyril
Messiou, Christina
Zaidi, Shane
Miah, Aisha B
Benson, Charlotte
Gennatas, Spyridon
Huang, Paul
Jones, Robin L
Abstract
Background/aim: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.
Patients and methods: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.
Results: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.
Conclusion: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2020-12
Type
Article
Other
Other
Subject
Collections
Citation
Cojocaru E, Thway K, Fisher C, Messiou C, Zaidi S, Miah AB, Benson C, Gennatas S, Huang P, Jones RL. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res. 2020 Dec;40(12):7003-7007. doi: 10.21873/anticanres.14725